Oncolytic alphavirus SFV-VA7 efficiently eradicates subcutaneous and orthotopic human prostate tumours in mice

Miika Martikainen*,1,2, Janne Ruotsalainen1,3, Johanna Tuomela4, Pirkko Härkönen4, Magnus Essand2, Jari Heikkilä5 and Ari Hinkkanen1

1Department of Biotechnology and Molecular Medicine, A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio 70211, Finland; 2Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala 75237, Sweden; 3Department of Dermatology, University Hospital Magdeburg, Magdeburg 39120, Germany; 4Institute of Biomedicine, University of Turku, Turku 20520, Finland and 5Department of Biochemistry and Pharmacy, Åbo Akademi University, Turku 20500, Finland

Background: Despite recent therapeutic and diagnostic advances, prostate cancer remains the second leading cause of cancer-related deaths among men in the Western world. Oncolytic viruses that replicate selectively in tumour cells represent a novel treatment candidate for these malignancies.

Methods: We analysed infectivity of avirulent Semliki Firest virus SFV-VA7 in human prostate cancer cell lines VCaP, LNCaP and 22Rv1 and in nonmalignant prostate epithelial cell line RWPE-1. Therapeutic potency of SFV-VA7 was evaluated in subcutaneous and orthotopic mouse LNCaP xenograft models.

Results: SFV-VA7 infected and killed the tested human prostate cancer cell lines irrespective of their hormone response status, while the nonmalignant prostate epithelial cell line RWPE-1 proved highly virus resistant. Notably, a single peritoneal dose of SFV-VA7 was sufficient to eradicate all subcutaneous and orthotopic LNCaP tumours.

Conclusions: Our results indicate that SFV-VA7 is a novel, promising therapeutic virus against prostate cancer warranting further testing in early clinical trials.
killed by SFV-VA7, whereas nonmalignant prostate cells displayed resistance to infection. Of the tested cell lines, malignant VCaP and nonmalignant RWPE-1 showed functional IFN-I response indicated by STAT1 phosphorylation. Peritonal administration of SFV-VA7 eradicated 100% of the large, established subcutaneous and orthotopic tumours without observed toxicities.

MATERIALS AND METHODS

Cell lines and viruses. RWPE-1 (ATCC) cells were cultured in keratinocyte serum-free medium supplemented with bovine pituitary extract and human recombinant epidermal growth factor (GIBCO). 22Rv1 (ATCC) and LNCaP cells were cultured in RPMI-1640 (Sigma-Aldrich, St Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS, Autogen Bioclear, Calne, UK) and 1% L-glutamine (Sigma-Aldrich). VCaP cells were cultured in Dulbecco’s Modified Eagle’s Medium (Sigma-Aldrich) supplemented with 10 FBS and 1% L-glutamine. All the used culture media were supplemented with 1% penicillin, streptomycin (Sigma-Aldrich). Production of replicative SFV VA7-EGFP and VA7-Rluc have been described earlier (Vähä-Koskela et al., 2003; Heikkilä et al., 2010).

Measuring of virus production. A total of 80 000 RWPE-1, 22Rv1 or VCaP cells were seeded on 12-well plate and infected 3 days later with VA7-EGFP (MOI = 0.01) in 1 ml volume. Cells were washed with PBS 2 h post infection (pi.) and fresh medium was added. Medium (200 µl) from two parallel wells was collected 48 and 72 h pi. for plaque titration (Ruotsalainen et al., 2015). Cell infections were carried out with SFV-VA7 viruses expressing either EGFP or Rluc transgene, which do not influence the infection (Heikkilä et al., 2010).

Cell viability assay. A total of 40 000 RWPE-1, 22Rv1, VCaP or LNCaP cells were seeded on 96–well plate and infected with VA7-EGFP using MOI = 0.01 – 10. Cell viability was measured from 3 to 4 parallel wells 4 days pi. with Cell proliferation Kit I (Roche Applied Science, Penzberg, Germany). LNCaP viability was measured with Calcein AM assay.

Western blot. To induce STAT1 phosphorylation, cells were treated with 1000 units per ml of human recombinant IFN-β (Nordic Biosite, Täby, Sweden) and incubated at +37 °C for 20 min. Expression of viral proteins and infection-induced STAT1 phosphorylation was detected from VA7-EGFP-infected cells MOI = 10, 18 h pi. Western blotting was performed as described before (Martikainen et al., 2015) using the following antibodies: Rabbit polyclonal antibody against nsP3 (kindly provided by Tero Ahola, Helsinki) or viral structural proteins (produced in house), rabbit anti-STAT1 (1:6111; BD Transduction Laboratories, Franklin Lakes, NJ, USA), rabbit anti-Tyr701-phosphorylated STAT1 (D4A7; Cell Signaling Technology, Danvers, MA, USA) and mouse anti-β-actin (C4, Santa Cruz Biotechnology, Santa Cruz, CA, USA). Anti-rabbit–Cy5 and anti-mouse–Cy3 (ECL Plex, GE Healthcare, Chicago, IL, USA) were used as secondary antibodies. Imaging was performed with a Typhoon scanner (GE Healthcare).

Immunohistochemistry. Brain and tumour tissue samples were collected from mice 72 h after intraperitoneal injection of 1 × 106 PFU VA7-EGFP virus or PBS. Parafomaldehyde-fixed and paraffin-embedded tissue sections were stained using the Vectastain ABC kit (rabbit IgG; Vector Laboratories, Burlingame, CA,
injection of 1–300 mm³ as measured with caliper (SigmaFast DAB; Sigma–Aldrich) was used for colour reaction.

**In vivo experiments.** CAnN.Cg-Foxn1nu/Crl Balb/c nude mice (Charles River) were used for the animal studies. Work was conducted following Finnish Board of Animal Experimentation guidelines, licence number ESAV1/3257/04.10.07/2014.

For subcutaneous tumours, 5 × 10⁶ LNCaP cells were injected in 100 μl volume of PBS/Matrigel (50 out of 50) into left flanks of mice. Tumour growth was stimulated with implanted testosterone pellet (10 mg, Innovative Research of America, Sarasota, FL, USA). Upon palpable tumours (100–300 mm³) as measured with caliper ((length × width²)/2), mice received a single intraperitoneal injection of 1 × 10⁸ PFU VA7-GFP in 100 μl PBS. PBS was used as the vehicle treatment. Mice were killed when tumour size reached 1000 mm³.

Orthotopic prostate tumours were induced as previously described (Tuomela et al, 2009). Briefly, a small incision was made above pubic symphysis and the bladder and seminal vesicles were carefully moved to expose the prostate. 5 × 10⁶ LNCaP cells in 20 μl volume of PBS/Matrigel were injected into the prostate. Prostate-specific antigen (PSA) secretion into serum was measured with PSA detection kit (Roche, Applied Science). Mice received a single intraperitoneal injection of 1 × 10⁸ PFU VA7-GFP in 100 μl PBS, when PSA was detectable.

### RESULTS

VA7-EGFP infects and kills human prostate cancer cell lines but not nonmalignant prostate epithelial cells. To test the feasibility of SFV-VA7 against prostate cancer, we first analysed its infectivity in vitro. Interestingly, even low multiplicity of infection (MOI) of SFV-VA7 efficiently infected and killed all tested VCaP, 22Rv1 and LNCaP prostate cancer cell lines (Figure 1A), whereas the nonmalignant RWPE-1 cells were significantly more resistant and displayed more than 100-fold reduction in supernatant viral titers (Figure 1B).

LNCaP and 22Rv1 prostate cancer cells have dysfunctional JAK/STAT signaling pathway. We have observed previously that poorly IFN-I responsive tumours represent susceptible targets to SFV-VA7 (Ruotsalainen et al, 2012, 2015). Thus, we next studied IFN-I responsiveness of the malignant and nonmalignant prostate cells. As expected, IFN-I treatment induced robust STAT1 phosphorylation in RWPE-1 and positive control cell line Vero(B). In contrast, out of the three studied prostate cancer cell lines LNCaP, VCaP and 22Rv1 only VCaP displayed STAT1 phosphorylation upon IFN-β treatment (Figure 1C). Whereas both RWPE-1 and VCaP cells were type I IFN responsive, only the nonmalignant cells were resistant to oncolytic infection. Thus, we proceeded to further analyse SFV-VA7 replication in these cells. Interestingly, SFV-VA7 infection itself did not induce STAT1 phosphorylation in RWPE-1 cells and only weakly in VCaP cells (Figure 1D). In line with the poor productive infection (Figure 1A), RWPE-1 cells also contained markedly less viral envelope proteins after infection, but interestingly highly similar levels of non-structural protein 3 (nsp3) (Figure 1D).

SFV-VA7 eradicates subcutaneous and orthotopic LNCaP tumours in vivo. We next analysed the oncolytic potency of SFV-VA7 in the LNCaP prostate cancer model in vivo. LNCaP was chosen due to its unresponsiveness to type I IFN, which was found to be the predominant phenotype in the tested malignant cells. In addition, according to literature, LNCaP is the most widely used cell line tested in oncolytic virotherapy in vivo and hence the obtained results were deemed readily comparable to those reported from earlier studies. Strikingly, progressively growing subcutaneous tumours in nude mice started shrinking after intraperitoneal injection of SFV-VA7 and disappeared in 24 days after treatment (Figure 2A and B). Importantly, high virus loads could be detected in the tumours 72 h after infection both by immunohistochemistry.

![Figure 2](https://www.bjcancer.com/DOI:10.1038/bjc.2017.151)

**Figure 2.** Intraperitoneally administered SFV-VA7 homes into subcutaneous LNCaP tumours and eradicates them. Tumour volumes (mean + range) measured in (A) untreated mice (n = 5) and (B) mice treated with single intraperitoneal dose of SFV-VA7 (n = 8, 1 × 10⁸ PFU). (C) Representative immunohistochemical staining of LNCaP tumour samples collected 72 h pi. Virus antigen stained brown. Scale bar 200 μm. (D) Titration of SFV-VA7 from collected tumour and brain samples 72 h pi. Star: not detected.
Intratumoural administration of oncolytic virus has been shown to be effective against prostate cancer xenografts (Schenk et al., 2014; Mansfield et al., 2016). Systemic administration would be preferable in targeting advanced disease but has usually shown clearly limited efficacy (Berry et al., 2008; Li et al., 2013). Furthermore, preclinical oncolytic virotherapy research in prostate cancer has relied heavily on subcutaneous tumour models due to the high technical demands of orthotopic inoculation. In one of the few studies available, conditionally replicating adenovirus AxdAdB-3 was reported to modestly improve the survival of SCID mice bearing orthotopic DU145 tumours after intratumoural administration (Satoh et al., 2007). In another study, macrophage-based delivery of an oncolytic adenovirus in combination with docetaxel and radiation therapy showed significantly increased survival in orthotopic LNCaP model (Muthana et al., 2013).

Here we report that all tested prostate cancer cell lines (LNCaP, VCaP and 22Rv1) were efficiently infected and killed in vitro by SFV-VA7, but nonmalignant RWPE-1 cells proved resistant. While the mechanism of RWPE-1 resistance to SFV-VA7 infection warrants further study, high viral ns3 protein levels after infection indicate that the inhibition takes place after viral entry and early expression of non-structural proteins.

A single peritoneal administration of SFV-VA7 resulted in a 100% cure rate both in subcutaneous and orthotopic LNCaP tumour models, thus suggesting that SFV-VA7 is a novel and highly promising option for treatment of prostate cancer and supporting early clinical testing. The fact that the used mice were immunosuppressed poses a potential caveat in clinical translation.

However, earlier we have shown that SFV-VA7 could destroy type I IFN unresponsive mouse colorectal tumours with equal efficiency in immunocompetent and immunosuppressed hosts (Ruotsalainen et al., 2015). Notably, both hormone responsive LNCaP and hormone unresponsive 22Rv1 displayed poor IFN-I responsiveness and were highly susceptible to SFV-VA7 lysis. This result is in line with earlier reports of IFN-I defects in a proportion of human prostate tumours (Danziger et al., 2016) and implies that SFV-VA7 could possibly be utilised as a salvage therapy in castration resistant prostate cancer.

ACKNOWLEDGEMENTS

This research was funded by Emil Aaltonen Foundation and Medicinska Undersökningsföreningen Liv och Hälsa.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

Berry LJ, Au GG, Barry RD, Shafren DR (2008) Potent oncolytic activity of human enteroviruses against human prostate cancer. *Prostate* 68: 577–587.

Danziger O, Shai B, Sabo Y, Bacharach E, Ehrlich M (2016) Combined genetic and epigenetic interferences with interferon signaling expose prostate cancer cells to viral infection. *Oncotarget* 7: 52115–52134.

Delwar Z, Zhang K, Rennie PS, Jia W (2016) Oncolytic virotherapy for urological cancers. *Nat Rev Urol* 13: 334–352.

Heikilä JE, Vähä-Koskela MJ, Ruotsalainen JJ, Martikainen MW, Stanford MM, McCart JA, Bell JC, Hinkkanen AE (2010) Intravenously administered alphavirus vector VA7 eradicates orthotopic human glioma xenografts in nude mice. *PloS One* 5: e8603.

Ketola A, Hinkkanen A, Yongabi F, Furu P, Määttä A-M, Liimatainen T, Pirinen R, Björn M, Hakkarainen T, Mäkinen K, Wahlfors J, Pellinen R (2008) Oncolytic Semliki forest virus vector as a novel candidate against unresectable osteosarcoma. *Cancer Res* 68: 8342–8350.

Li H, Nakashima H, Decklever TD, Nace RA, Russell SJ (2013) HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy. *Cancer Gene Ther* 20: 478–485.

Mansfield DC, Kyula JN, Rosenfelder N, Chao-Chu J, Kramer-Marek G, Khan AA, Roublé V, McLaughlin M, Melcher AA, Vile RG, Pandha HS, Khoov, Harrington KJ (2016) Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer. *Gene Ther* 23: 357–368.

Martikainen M, Niittykoski M, von und zu Fraunberg M, Immonen A, Koponen S, van Geenen M, Vähä-Koskela M, Ylösmäki E, Jääskeläinen JE, Saksela K, Hinkkanen A (2015) MicroRNA-attenuated clone of virulent semliki forest virus overcomes antiviral type I interferon in resistant mouse CT-2A glioma. *J Virol* 89: 10637–10647.

Muthana M, Rodrigues S, Chen Y-Y, Welford A, Hughes R, Tazzyman S, Essand M, Morrow F, Lewis CE (2013) Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation. *Cancer Res* 73: 490–495.

Määttä A-M, Mäkinen K, Ketola A, Liimatainen T, Yongabi FN, Vähä-Koskela M, Pirinen R, Rautio O, Pellinen R, Hinkkanen A, Wahlfors J (2008) Replication competent Semliki Forest virus prolongs survival in experimental lung cancer. *Int J Cancer* 123: 1704–1711.

Ruotsalainen J, Martikainen M, Niittykoski M, Huhtala T, Aaltonen T, Heikilä J, Bell J, Vähä-Koskela M, Hinkkanen A (2012) Interferon-β sensitivity of tumor cells correlates with poor response to VA7 virotherapy in mouse glioma models. *Mol Ther* 20: 1529–1539.

www.bjcancer.com | DOI:10.1038/bjc.2017.151
Ruotsalainen JJ, Kaikkonen MU, Niittykoski M, Martikainen MW, Lemay CG, Cox J, De Silva NS, Kus A, Falls TJ, Diallo J-S, Le Bœuf F, Bell JC, Ylä-Herhtuala S, Hinkkanen AE, Vähä-Koskela MJ (2015) Clonal variation in interferon response determines the outcome of oncolytic virotherapy in mouse CT26 colon carcinoma model. *Gene Ther* **22**: 65–75.

Satoh M, Wang H, Ishidoya S, Abe H, Moriya T, Hamada H, Arai Y (2007) Oncolytic virotherapy for prostate cancer by E1A, E1B mutant adenovirus. *Urology* **70**: 1243–1248.

Schenk E, Essand M, Kraaij R, Adamson R, Maitland NJ, Bangma CH (2014) Preclinical safety assessment of Ad[I/PPT-E1A], a novel oncolytic adenovirus for prostate cancer. *Hum Gene Ther Clin Dev* **25**: 7–15.

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. *CA Cancer J Clin* **66**: 7–30.

Tuomela J, Valta M, Seppänen J, Tarkkonen K, Vääänänen HK, Härkönen P (2009) Overexpression of vascular endothelial growth factor C increases growth and alters the metastatic pattern of orthotopic PC-3 prostate tumors. *BMC Cancer* **9**: 362.

Vähä-Koskela MJV, Tuittila M, Nygårdas PT, Nyman JK-E, Ehrengruber MU, Renggli M, Hinkkanen AE (2003) A novel neurotropic expression vector based on the avirulent A7(74) strain of Semliki Forest virus. *J Neurovirol* **9**: 1–15.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.